...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Sarcoma >Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience
【24h】

Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience

机译：成人与小儿神经母细胞瘤：M.D. Anderson癌症中心的经验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. Staging and treatment of adult neuroblastoma has yet to be formalized. We sought to determine the utility of the pediatric classification system in adults and determine the efficacy of different treatment modalities.Methods. Medical records of 118 adults (patients >17 years old) and 112 pediatric patients (ages 2–17), who were treated for neuroblastoma at M.D. Anderson Cancer Center from January 1994 to September 2012, were reviewed. International neuroblastoma risk group (INRG) variables were abstracted. The primary outcome of interest was actuarial progression-free survival.Results. Median age of pediatric patients was 5 years (range 3–16) and 47 years (range 18–82) for adult patients. There were no differences in PFS or OS between stage-matched risk categories between pediatric and adult patients (L1-P=0.40, L2-P=0.54, and M-P=0.73). In the treatment of L1 disease, median PFS for adults treated with surgery and radiation was 11.1 months compared with single modality local treatment ± chemotherapy (6.4 and 5.1 months, resp.;P=0.07). Median PFS in L2 adult patients was 5.2 months with local therapy and 4 months with the addition of chemotherapy (P=0.23).Conclusions. Adult and pediatric patients with neuroblastoma achieve similar survival outcomes. INRG classification should be employed to stratify adult neuroblastoma patients and help select treatment.
机译：背景。成人神经母细胞瘤的分期和治疗尚待正规化。我们试图确定小儿分类系统在成人中的效用，并确定不同治疗方式的疗效。回顾了1994年1月至2012年9月在安德森癌症中心接受神经母细胞瘤治疗的118例成人（> 17岁以上患者）和112例小儿患者（2-17岁）的病历。国际神经母细胞瘤风险组（INRG）变量被抽象出来。感兴趣的主要结果是精算无进展生存期。成人患者的中位年龄为5岁（3-16岁），47岁（18-82岁）。小儿和成年患者的阶段匹配风险类别之间的PFS或OS没有差异（L1-P = 0.40，L2-P = 0.54和M-P = 0.73）。在L1疾病的治疗中，接受手术和放射治疗的成年人的中位PFS为11.1个月，而单模式局部治疗±化疗的时间为6.4和5.1个月，分别为P = 0.07。在L2成年患者中，局部治疗的中位PFS为5.2个月，加化疗后为4个月（P = 0.23）。成年和小儿神经母细胞瘤患者可达到相似的生存结果。应采用INRG分类对成年神经母细胞瘤患者进行分层并帮助选择治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号